Compare · INGN vs SNN
INGN vs SNN
Side-by-side comparison of Inogen Inc (INGN) and Smith & Nephew SNATS Inc. (SNN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INGN and SNN operate in Industrial Specialties (Health Care), so they compete in similar markets.
- SNN is the larger of the two at $12.58B, about 71.0x INGN ($177.1M).
- Over the past year, INGN is down 7.6% and SNN is down 0.8% - SNN leads by 6.9 points.
- SNN has been more active in the news (11 items in the past 4 weeks vs 10 for INGN).
- SNN has more recent analyst coverage (23 ratings vs 11 for INGN).
- Company
- Inogen Inc
- Smith & Nephew SNATS Inc.
- Price
- $6.52+1.40%
- $29.60+0.71%
- Market cap
- $177.1M
- $12.58B
- 1M return
- +1.80%
- -3.74%
- 1Y return
- -7.65%
- -0.79%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 10
- 11
- Recent ratings
- 11
- 23
Inogen Inc
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
Smith & Nephew SNATS Inc.
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.
Latest INGN
- SEC Form S-8 filed by Inogen Inc
- Director Sahney Mira Kirti was granted 28,081 shares, increasing direct ownership by 71% to 67,805 units (SEC Form 4)
- Director Jamali Vafa was granted 28,081 shares, increasing direct ownership by 187% to 43,081 units (SEC Form 4)
- Director Boehnlein Glenn S was granted 28,081 shares, increasing direct ownership by 37% to 104,966 units (SEC Form 4)
- Director Rider Heather D. was granted 28,081 shares, increasing direct ownership by 32% to 116,282 units (SEC Form 4)
- Director Mora Elizabeth was granted 28,081 shares, increasing direct ownership by 35% to 107,261 units (SEC Form 4)
- Director Ladone Mary Kay was granted 28,081 shares, increasing direct ownership by 37% to 104,966 units (SEC Form 4)
- Director King Kevin M was granted 28,081 shares, increasing direct ownership by 37% to 104,966 units (SEC Form 4)
- New insider Jamali Vafa claimed ownership of 15,000 shares (SEC Form 3)
- EVP Entrprs Enblmnt, Ch HR Off Yi Boyer Jennifer M sold $70,313 worth of shares (10,770 units at $6.53) as part of a pre-agreed trading plan, decreasing direct ownership by 40% to 15,977 units (SEC Form 4)
Latest SNN
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- A Fresh FDA Catalyst Is Putting Regenerative Wound Care in Focus
- Smith+Nephew announces first clinical cases with the next generation CORI◊XT Handheld Robotics Platform across knee and shoulder arthroplasty
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- Smith & Nephew downgraded by Kepler
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- Smith+Nephew launch next generation LEAF™ Patient Monitoring System – an innovative pressure injury prevention platform delivering proven clinical impact